Table 1.

Emetic risk groups according to MASCC

Risk	Cytostatics
High	Cisplatin, mechlorethamine, streptozocin, cyclophosphamide >1,500 mg/m2, carmustine, dacarbazin
	Oral: Hexamethylmelamine, procarbazine
Moderate	Oxaliplatin, cytarabine >1,000 mg/m2, carboplatin, ifosfamide, cyclophosphamide <1,500 mg/m2, azacitidine, alemtuzumab, doxorubicin, daunorubicin, epirubicin, idarubicin, irinotecan, bendamustine, clofarabine
	Oral: Cyclophosphamide, temozolomide, vinorelbine, imatinib
Low	Paclitaxel, docetaxel, mitoxantrone, topotecan, etoposide, pemetrexed, methotrexate, doxorubicin HCl liposome injection, temsirolimus, ixabepilone, mitomycin, gemcitabine, cytarabine <1,000 mg/m2, 5-fluorouracil, bortezomib, cetuximab, trastuzumab, catumaxomab, panitumumab
	Oral: Capecitabine, tegafur uracil, etoposide, sunitinib, fludarabine, everolimus, lapatinib, lenalidomide, thalidomide
Minimal	Bleomycin, busulfan, cladribine, fludarabine, vinblastine, vincristine
	vinorelbine, bevacizumab
	Oral: chlorambucil, hydroxyurea, melphalan, methotrexate, 6-thioguanine
	gefitinib, sorafenib, erlotinib